Keeping our adult patients healthy and active: The role of vaccines across the lifespan

Physician and Sportsmedicine

Volumn 38, Issue 4, 2010, Pages 35-47

  Schaffner, William ^a,b   Rehm, Susan J ^a,c   File Jr , Thomas M ^a,d  

^a National Foundation for Infectious Diseases (NFID)   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d SUMMA HEALTH SYSTEM   (United States)

Author keywords

Adult; Immunization; Influenza; Pertussis; Preventive care; Preventive practice; Vaccines

Indexed keywords

CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; MEASLES VACCINE; MENINGOCOCCUS VACCINE; MUMPS VACCINE; PNEUMOCOCCUS VACCINE; RUBELLA VACCINE; WART VIRUS VACCINE;

BACTERIAL TRANSMISSION; CHICKENPOX; CLINICAL FEATURE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DAILY LIFE ACTIVITY; DISEASE TRANSMISSION; HEALTH CARE COST; HEPATITIS A; HEPATITIS B; HERPES ZOSTER; HUMAN; IMMUNITY; INCIDENCE; INFECTION PREVENTION; INFLUENZA; LIFE EXTENSION; LIFESPAN; MEASLES; MENINGOCOCCOSIS; MUMPS; PAPILLOMAVIRUS INFECTION; PATIENT CARE; PERTUSSIS; PNEUMOCOCCAL INFECTION; REVIEW; RISK FACTOR; RUBELLA; SEASONAL INFLUENZA; SEXUAL BEHAVIOR; TREATMENT CONTRAINDICATION; UNITED STATES; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VIRUS REACTIVATION; VIRUS TRANSMISSION;

ADULT; HUMANS; IMMUNIZATION SCHEDULE; PRIMARY PREVENTION; RISK FACTORS; SPORTS MEDICINE; TRAVEL; VACCINATION;

EID: 78650266978     PISSN: 00913847     EISSN: None     Source Type: Journal    
DOI: 10.3810/psm.2010.12.1823     Document Type: Review

References (81)

1. Advisory Committee on Immunization Practices. Recommended adult immunization schedule - United States, 2010. Ann Intern Med. 2010;152(1):36-39.
2. Centers for Disease Control and Prevention. Adult vaccination coverage, NHIS. http://www.cdc.gov/vaccines/stats-surv/nhis/2009-nhis.htm. Accessed November 17, 2010.
3. Anon. 10 Reasons to be vaccinated. National Foundation for Infectious Diseases: Bethesda, MD, 2009. http://www.adultvaccination.org/doc/10-reasons. pdf. Accessed September 2, 2010.
4. Cox NJ, Subbarao K. Influenza. Lancet. 1999;354(9186):1277-1282.
5. Fiore AE, Uyeki TM, Broder K, et al; Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010;59(RR-8):1-62.
6. Ciszewski A, Bilinska ZT, Brydak LB, et al. Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study. Eur Heart J. 2008;29(11):1350-1358. (Pubitemid 351806477)
7. Poole PJ, Chacko E, Wood-Baker RW, Cates CJ. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;1:CD002733.
8. Hak E, Buskens E, van Essen GA, et al. Clinical effectiveness of influenza vaccination in persons younger than 65 years with high-risk medical conditions: the PRISMA study. Arch Intern Med. 2005;165(3):274-280.
9. Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med. 1995;123(7):518-527.
10. Nichol KL, Lind A, Margolis KL, et al. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med. 1995;333(14):889- 893.
11. Centers for Disease Control and Prevention. Influenza. In: Atkinson W, Wolfe S, Hamborsky J, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 11th ed. Washington, DC: Public Health Foundation; 2009. http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/pert.pdf. Accessed September 2, 2010.
12. Centers for Disease Control and Prevention. Updated CDC estimates of 2009 H1N1 influenza cases, hospitalizations and deaths in the United States, April 2009 - April 10, 2010. http://www.cdc.gov/h1n1flu/estimates-2009-h1n1.htm. Accessed September 2, 2010.
13. Viboud C, Miller M, Olson D, Osterholm M, Simonsen L. Preliminary estimates of mortality and years of life lost associated with the 2009 A/H1N1 pandemic in the US and comparison with past influenza seasons. PLoS Curr. 2010;2:RRN1153.
14. Nicholson KG. Clinical features of influenza. Semin Respir Infect. 1992;7(1):26-37.
15. Barker WH. Excess pneumonia and influenza associated hospitalization during influenza epidemics in the United States, 1970-78. Am J Public Health. 1986;76(7):761-765.
16. Monto AS, Kioumehr F. The Tecumseh Study of Respiratory Illness. IX. Occurrence of influenza in the community, 1966-1971. Am J Epidemiol. 1975;102(6):553-563.
17. McCullers JA, Facchini S, Chesney PJ, Webster RG. Influenza B virus encephalitis. Clin Infect Dis. 1999;28(4):898-900.
18. Morishima T, Togashi T, Yokota S, et al; Collaborative Study Group on Influenza-Associated Encephalopathy in Japan. Encephalitis and encephalopathy associated with an influenza epidemic in Japan. Clin Infect Dis. 2002;35(5):512-517.
19. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289(2):179-186. (Pubitemid 36068705)
20. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA. 2004;292(11):1333-1340.
21. Kech M, Beardsworth P. The impact of influenza on working days lost: a review of the literature. Pharmacoeconomics. 2008;26(11):911-924.
22. Molinari NA, Ortega-Sanchez IR, Messonnier ML, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007;25(27):5086-5096.
23. IDSA News. ACIP targets pertussis vaccination gaps. http://news. idsociety.org/idsa/issues/2010-10-01/2.html. Accessed November 1, 2010.
24. California Department of Public Health. Pertussis report, 8/17/2010. http://www.cdph.ca.gov/programs/immunize/Documents/PertussisReport9-28-2010.pdf. Accessed October 4, 2010.
25. California Department of Public Health. CDPH broadens recommendations for vaccinating against pertussis: immunization key to controlling whooping cough. http://www.cdph.ca.gov/Pages/PH10-048.aspx. Accessed October 4, 2010.
26. Centers for Disease Control and Prevention. Diphtheria, tetanus, and pertussis: recommendations of the Immunization Practices Advisory committee (ACIP). MMWR Recomm Rep. 1991;40(RR-10):1-28.
27. Centers for Disease Control and Prevention (CDC). Pertussis. In: Atkinson W, Wolfe S, Hamborsky J, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 11th ed. Washington, DC: Public Health Foundation; 2009. http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/pert.pdf. Accessed September 2, 2010.
28. Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J. 2005;24(5suppl):S58-S61.
29. Centers for Disease Control and Prevention. Notice to readers: final 2009 reports of national notifiable infectious diseases. MMWR. 2010;59(32):1025- 1027-1039.
30. Kretsinger K, Broder KR, Cortese MM, et al; Advisory Committee on Immunization Practices; Healthcare Infection Control Practices Advisory Committee. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR Recomm Rep. 2006;55(RR-17):1-37.
31. Centers for Disease Control and Prevention (CDC). Pertussis-United States, 1997-2000. MMWR Morb Mortal Wkly Rep. 2002;51(4): 73-76.
32. Jackson AD. The Ohio Department of Health encourages back to school immunizations. August 2010. http://www.odh.ohio.gov/landing/jackson/columns. aspx. Accessed October 7, 2010.
33. Michigan Department of Community Health. Pertussis (whooping cough) in Michigan. http://www.michigan.gov/mdch/0,1607,7-132-2942-4911-4914-240419--,00. html. Accessed October 7, 2010.
34. New York Department of Health. State health commissioner urges vaccination for pertussis (whooping cough) as number of pertussis cases climbs above this period last year. http://www.nyhealth.gov/press/releases/2010/2010- 09-24-pertussis.htm. Accessed October 7, 2010.
35. Pennsylvania Department of Health. 2010-PAHAN-0193-08-05-ADV - Pertussis. http://www.portal.health.state.pa.us/portal/server.pt/community/health-alert- network/14217. Accessed October 7, 2010.
36. South Carolina Department of Health and Environmental Control. Pertussis cases increasing, especially among infants. http://www.scdhec.gov/health/ disease/han/docs/HAN-20100608-01.pdf. Accessed October 7, 2010.
37. Centers for Disease Control and Prevention. Pertussis. Number of reported cases, by age group - United States, 2007. http://www.cdc.gov/ncphi/disss/ nndss/annsum/2007/07graphs.htm. Accessed September 2, 2010.
38. Cortese MM, Baughman AL, Brown K, Srivastava P. A "new age" in pertussis prevention new opportunities through adult vaccination. Am J Prev Med. 2007;32(3):177-185.
39. Bisgard KM, Pascual FB, Ehresmann KR, et al. Infant pertussis: who was the source? Pediatr Infect Dis J. 2004;23(11):985-989.
40. Healy CM, Munoz FM, Rench MA, Halasa NB, Edwards KM, Baker CJ. Prevalence of pertussis antibodies in maternal delivery, cord, and infant serum. J Infect Dis. 2004;190(2):335-340.
41. World Health Organization. 23-valent pneumococcal polysaccharide vaccine. WHO position paper. Wkly Epidemiol Rec. 2008;83(42):373-384.
42. Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2008;1:CD000422.
43. Rehm SJ, Farley MM, File TM Jr, et al. Higher pneumococcal disease vaccination rates needed to protect more at-risk US adults. Postgrad Med. 2009;121(6):101-105.
44. Centers for Disease Control and Prevention. Pneumococcal disease. In: Atkinson W, Wolfe S, Hamborsky J, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 11th ed. Washington, DC: Public Health Foundation; 2009. http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/pert.pdf. Accessed September 2, 2010.
45. File TM. Community-acquired pneumonia. Lancet. 2003;362(9400): 1991-2001.
46. Jackson ML, Neuzil KM, Thompson WW, et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis. 2004;39(11):1642-1650.
47. Mandell LA, Wunderink RG, Anzueto A, et al; Infectious Diseases Society of America, American Thoracic Society Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(suppl2):S27- S72.
48. Centers for Disease Control and Prevention. 2010. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Streptococcus pneumoniae, provisional-2009. http://www.cdc.gov/abcs/reports-findings/ survreports/spneu09.pdf. Accessed September 15, 2010.
49. File TM, Marrie TJ. Burden of community-acquired pneumonia in North American adults. Postgrad Med. 2010;122(2):130-141.
50. Immunization Action Coalition. Ask the experts: Pneumococcal polysaccharide vaccine (PPSV). http://www.immunize.org/askexperts/experts-ppv. asp. Accessed October 7, 2010.
51. Centers for Disease Control and Prevention. Human papillomavirus. In: Atkinson W, Wolfe S, Hamborsky J, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 11th ed. Washington, DC: Public Health Foundation; 2009. http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/pert.pdf. Accessed September 2, 2010.
52. Centers for Disease Control and Prevention. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010;59(20):630-632.
53. Center for Disease Control and Prevention. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR 2010;59(20):626-629.
54. Gardasil [package insert]. Whitehouse Station, NC: Merck and Co. Inc; 2009.
55. Winer RL, Feng Q, Hughes JP, O'Reilly S, Kiviat NB, Koutsky LA. Risk of female human papillomavirus acquisition associated with first male sex partner. J Infect Dis. 2008;197(2):279-282.
56. Dunne EF, Unger ER, Maya Sternberg S, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007;297(8):813-819.
57. Schiffman MH, Brinton LA. The epidemiology of cervical carcinogenesis. Cancer. 1995;76(10 suppl):1888-1901.
58. Centers for Disease Control and Prevention. Genital HPV infection - CDC fact sheet. November 2009. http://www.cdc.gov/std/HPV/STDFact-HPV.htm. Accessed September 13, 2010.
59. Dunne EF, Nielson CM, Stone KM, Markowitz LE, Giuliano AR. Prevalence of HPV infection among men: a systematic review of the literature. J Infect Dis. 2006;194(8):1044-1057. (Pubitemid 44547644)
60. Weinstock H, Berman S, Cates W Jr. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health. 2004;36(1):6-10.
61. Muñoz N, Bosch FX, Desanjosé S, et al. The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Colombia and Spain. Int J Cancer. 1992;52(5):743-749.
62. Schiffman MH, Bauer HM, Hoover RN, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst. 1993;85(12):958-964.
63. American Cancer Society. Cancer facts and figures 2010. http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/ cancer-facts-and-figures-2010. Accessed September 13, 2010.
64. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003;88(1):63-73. (Pubitemid 36241220)
65. Parkin DM, Bray F Chapter 2: the burden of HPV-related cancers. Vaccine. 2006;24(suppl3):11-25.
66. Insinga RP, Dasbach EJ, Elbasha EH. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics. 2005;23(11):1107-1122.
67. Oxman MN, Levin MJ, Johnson GR, et al; Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271-2284.
68. Kilgore PE, Kruszon-Moran D, Seward JF, et al. Varicella in Americans from NHANES III: implications for control through routine immunization. J Med Virol. 2003;70(suppl 1):S111-S118. (Pubitemid 36368856)
69. Arvin AM. Varicella-zoster virus. Clin Microbiol Rev. 1996;9(3): 361-381.
70. Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med. 2005;20(8):748-753. (Pubitemid 41141008)
71. McDonald JR, Zeringue AL, Caplan L, et al. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis. 2009;48(10):1364-1371.
72. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82(11):1341-1349.
73. Hope-Simpson RE. The nature of herpes zoster: a long-term study and new hypothesis. Proc Royal Soc Med. 1965;58:9-20.
74. Gilden DH, Dueland AN, Cohrs R, Martin JR, Kleinschmidt-DeMasters BK, Mahalingam R. Preherpetic neuralgia. Neurology. 1991;41(8): 1215-1218.
75. Mazur MH, Dolin R. Herpes zoster at the NIH: a 20 year experience. Am J Med. 1978;65(5):738-744. (Pubitemid 9067004)
76. Josephson A, Gombert ME. Airborne transmission of nosocomial varicella from localized zoster. J Infect Dis. 1988;158(1):238-241.
77. Kost RG, Straus SE. Postherpetic neuralgia - pathogenesis, treatment, and prevention. N Engl J Med. 1996;335(1):32-42. (Pubitemid 26230812)
78. Lydick E, Epstein RS, Himmelberger D, White CJ. Herpes zoster and quality of life: a self-limited disease with severe impact. Neurology. 1995;45 (12 suppl 8):S52-S53. (Pubitemid 26163687)
79. Ragozzino MW, Melton LJ 3rd, Kurland LT, Chu CP, Perry HO. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore). 1982;61(5):310-316. (Pubitemid 12031812)
80. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR-5):1-30.
81. Gnann JW Jr. Varicella-zoster virus: atypical presentations and unusual complications. J Infect Dis. 2002;186(suppl 1):S91-S98. (Pubitemid 35178855)